Market Beat
2024.09.28 11:10
portai
I'm PortAI, I can summarize articles.

Hennessy Advisors, Inc. (NASDAQ:HNNA) Director Susan Weber Pomilia Sells 1,073 Shares

Hennessy Advisors, Inc. (NASDAQ:HNNA) Director Susan Weber Pomilia sold 1,073 shares at an average price of $0.82, totaling $878.86. Post-sale, she retains 53,464 shares valued at approximately $43,016.48. The transaction was disclosed to the SEC. HNNA shares opened at $0.81, with a market cap of $33 million and a P/E ratio of 14.43. The company recently announced a quarterly dividend of $0.138 per share, yielding 5.63%. Renaissance Technologies LLC increased its stake in Hennessy Advisors by 1.9% in Q2.

Hennessy Advisors, Inc. (NASDAQ:HNNA - Get Free Report) Director Susan Weber Pomilia sold 1,073 shares of the company's stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $9.82, for a total value of $10,536.86. Following the completion of the sale, the director now owns 53,464 shares in the company, valued at $525,016.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Hennessy Advisors Trading Up 4.4 %

Shares of HNNA stock opened at $9.81 on Friday. The company has a market capitalization of $75.33 million, a price-to-earnings ratio of 14.43 and a beta of 0.80. The company has a current ratio of 17.39, a quick ratio of 17.39 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $9.39 and a 200 day moving average price of $7.88. Hennessy Advisors, Inc. has a twelve month low of $6.33 and a twelve month high of $11.99.

Hennessy Advisors (NASDAQ:HNNA - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The asset manager reported $0.26 earnings per share for the quarter. Hennessy Advisors had a net margin of 22.53% and a return on equity of 6.89%. The business had revenue of $7.79 million during the quarter.

Hennessy Advisors Announces Dividend


Jovine Was Right in 2008—Will You Listen This Time?

From Behind the Markets | Ad

The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.

Take these 4 steps today to protect your retirement NOW


The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 5th. Stockholders of record on Thursday, August 22nd were issued a dividend of $0.138 per share. This represents a $0.55 annualized dividend and a dividend yield of 5.63%. The ex-dividend date of this dividend was Thursday, August 22nd. Hennessy Advisors's dividend payout ratio (DPR) is 80.88%.

Institutional Investors Weigh In On Hennessy Advisors

A hedge fund recently raised its stake in Hennessy Advisors stock. Renaissance Technologies LLC raised its stake in shares of Hennessy Advisors, Inc. (NASDAQ:HNNA - Free Report) by 1.9% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 95,588 shares of the asset manager's stock after purchasing an additional 1,813 shares during the period. Renaissance Technologies LLC owned 1.24% of Hennessy Advisors worth $681,000 at the end of the most recent reporting period. 10.31% of the stock is currently owned by hedge funds and other institutional investors.

About Hennessy Advisors

(Get Free Report)

Hennessy Advisors, Inc is an employee owned investment manager. It provides its services to Hennessy Funds and investment companies. The firm launches and manages equity, fixed income, and balanced mutual funds. It invests in the public equity and fixed income markets across the globe. The firm primarily invests in growth stocks of companies.

Recommended Stories

  • Five stocks we like better than Hennessy Advisors
  • Pros And Cons Of Monthly Dividend Stocks
  • MarketBeat Week in Review – 9/23 - 9/27
  • Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed
  • Wake Up to This Biotech Stock That Still Has Big Potential Upside
  • 3 Fintech Stocks With Good 2021 Prospects
  • 3 Consumer Discretionary Stocks Poised for Growth

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Hennessy Advisors?

Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Hennessy Advisors and related companies.

More From MarketBeat

Fed Triggers Boom: Buy this Play on Elon’s New AI

Have you seen Elon Musk's new invention? I was already very bullish on this new type of AI. And now that...

InvestorPlace

7 Energy Stocks with Attractive High-Yield Dividends

With interest rates likely to move lower starting with the Federal Reserve's September meeting, many investors...

MarketBeat

The election trade you can't lose

Politics is an unpredictable game. But no matter what happens in the next few months... There's one thin...

Investors Alley

7 Attractive Dividend Stocks Under $50

As we head into the home stretch of 2024, the playbook for growth investors is the same as one year ago. You'r...

MarketBeat

10X More Profitable Than Physical Gold?

The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...

Monument Traders Alliance

7 Retail Stocks to Buy for a Back-to-School Surge

Advice like “skate where the puck is going" may sound like billboard investing, but there's a lot of tru...

MarketBeat

Buffett Dumps $982 Million in BofA Stock—What Does He Know?

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...

Genesis Gold Group

7 Mighty Medical Stocks That Will Keep Getting Stronger

Medical stocks are a broad category that covers pharmaceutical companies, health insurers, medical technology ...

MarketBeat